NASDAQ: EFTREffector Therapeutics Inc Stock
$1.01-0.16 (-13.68%)
Updated Jun 5, 2023
EFTR Price
$1.01
Fair Value Price
$1.38
Market Cap
$42.83M
52 Week Low
$0.34
52 Week High
$1.99
P/E
-1.17x
P/B
-8.9x
P/S
4.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.55M
Earnings
-$35.75M
Gross Margin
100%
Operating Margin
-936.87%
Profit Margin
-1,006.1%
Debt to Equity
-5.56
Operating Cash Flow
-$27M
Beta
0.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EFTR Overview
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cancer treatments. Its lead product candidates are Tomivosertib and Zotatifin. It has a collaboration agreement with Pfizer Inc. eFFECTOR Therapeutics was founded in 2012 and is headquartered in Solana Beach, CA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EFTR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EFTR ($1.01) is undervalued by 26.89% relative to our estimate of its Fair Value price of $1.38 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EFTR ($1.01) is significantly undervalued by 26.89% relative to our estimate of its Fair Value price of $1.38 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EFTR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EFTR due diligence checks available for Premium users.
Be the first to know about important EFTR news, forecast changes, insider trades & much more!
EFTR News
Valuation
EFTR fair value
Fair Value of EFTR stock based on Discounted Cash Flow (DCF)
Price
$1.01
Fair Value
$1.38
Undervalued by
26.89%
EFTR ($1.01) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EFTR ($1.01) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EFTR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EFTR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.17x
Industry
11.59x
Market
53.21x
EFTR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.9x
Industry
5.21x
EFTR's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.0M
Profit Margin
0%
EFTR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EFTR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$21.9M
Liabilities
$26.7M
Debt to equity
-5.56
EFTR's short-term liabilities ($26.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EFTR's short-term assets ($20.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EFTR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EFTR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.6M
Investing
$9.0M
Financing
$212.0k
EFTR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EFTR vs Biotech Stocks
Effector Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.